The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

This study is testing a new drug called AVM0703 for people with certain types of blood cancers (B-cell lymphomas, leukemias, and related conditions) that have come back or are no longer responding to prior treatments, including stem cell transplant or CAR T-cell therapy. AVM0703 works differently from standard treatments by activating a specific type of immune cell. **You may be eligible if...** - You are 12 years or older and weigh at least 40 kg (about 88 lbs) - You have a confirmed diagnosis of a specific type of lymphoma or leukemia (including DLBCL, high-grade B-cell lymphoma, mantle cell lymphoma, Burkitt lymphoma, CLL, or acute leukemia) - Your cancer has come back or stopped responding after prior therapies, including CAR T-cell therapy or stem cell transplant - Standard treatments are no longer effective or available for you **You may NOT be eligible if...** - You have not yet tried standard treatments for your type of lymphoma - Your cancer type is not included in the study - You have conditions that could interfere with the study treatment or evaluation Talk to your doctor to see if this trial is right for you.